Rubicatin/Rubitidine Price Analysis and Purchasing Channels: Latest Trends in 2025
Lurbinectedin, as a new type of anti-cancer drug, has been launched in many countries and regions, especially for the treatment of small cell lung cancer (SCLC) and other malignant tumors. The common specification is4MG per tube. With the widespread use of the drug, the price of rubicatin has become a focus of concern among patients. At present, the pricing of Rubicatin is relatively expensive, and its price varies according to different regions and sales channels. In particular, the pricing of the original drug is relatively high.
As of 2025, the price of Rubicon in overseas markets will still be at a relatively high level. In the United States, the price of Rubicatin’s original drug is approximately more than 90,000 yuan per box. This price is mainly based on the cost of imported drugs and the pricing strategy of the U.S. market. In comparison, Singapore's Ruby Cardin is relatively affordable, with the price per box being approximately RMB 30,000. The price of Rubicatin in the Hong Kong market is relatively low, with a box of 4mg priced at more than RMB 20,000. It should be noted that these prices will fluctuate based on exchange rate changes and charging standards from different channels, so patients need to pay attention to the latest market prices when purchasing drugs.
Although the price of the original drug of Rubicatin is relatively high, there are currently no generic drugs available in overseas markets, so patients can only purchase the original version. In terms of price, although original drugs are relatively expensive, in some countries or regions, patients can obtain certain cost reductions through medical insurance, government subsidies, or specific patient assistance programs.
For Chinese patients, access to rubicatin is limited. Since the drug is not yet available in mainland China, patients usually need to purchase drugs overseas to obtain the drug. For more information on overseas drug prices and related information, please consult Yaode Medical Consultants.
Reference materials:https://www.zepzelca.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)